Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 32 | 2025 | 540 | 10.010 |
Why?
|
Carcinoma, Pancreatic Ductal | 8 | 2025 | 138 | 3.290 |
Why?
|
Immunotherapy | 7 | 2025 | 160 | 3.290 |
Why?
|
Cachexia | 4 | 2024 | 53 | 2.880 |
Why?
|
Cation Transport Proteins | 5 | 2025 | 60 | 2.840 |
Why?
|
Neoplasms | 5 | 2025 | 808 | 2.250 |
Why?
|
Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 1.930 |
Why?
|
Biomarkers, Tumor | 10 | 2025 | 404 | 1.770 |
Why?
|
Cell Line, Tumor | 24 | 2025 | 1319 | 1.730 |
Why?
|
Glioblastoma | 5 | 2025 | 105 | 1.490 |
Why?
|
Extracellular Vesicles | 2 | 2025 | 43 | 1.490 |
Why?
|
Tumor Microenvironment | 6 | 2025 | 177 | 1.460 |
Why?
|
Gene Expression Regulation, Neoplastic | 11 | 2021 | 465 | 1.460 |
Why?
|
Humans | 55 | 2025 | 28094 | 1.350 |
Why?
|
Adenocarcinoma | 3 | 2020 | 298 | 1.210 |
Why?
|
Mice | 26 | 2025 | 4650 | 1.200 |
Why?
|
Genomics | 3 | 2023 | 123 | 1.130 |
Why?
|
Antineoplastic Agents | 6 | 2021 | 679 | 1.030 |
Why?
|
Animals | 31 | 2025 | 10415 | 1.020 |
Why?
|
Brain Neoplasms | 3 | 2025 | 301 | 1.000 |
Why?
|
Disease Models, Animal | 11 | 2024 | 1459 | 0.970 |
Why?
|
Antigens, Neoplasm | 2 | 2025 | 56 | 0.960 |
Why?
|
Precision Medicine | 4 | 2022 | 76 | 0.950 |
Why?
|
HLA Antigens | 1 | 2025 | 61 | 0.950 |
Why?
|
Signal Transduction | 12 | 2025 | 1435 | 0.940 |
Why?
|
Microglia | 1 | 2025 | 64 | 0.910 |
Why?
|
Zinc | 2 | 2025 | 63 | 0.910 |
Why?
|
Epitopes | 1 | 2025 | 183 | 0.890 |
Why?
|
Exosomes | 2 | 2023 | 96 | 0.860 |
Why?
|
Epithelial-Mesenchymal Transition | 3 | 2021 | 115 | 0.850 |
Why?
|
Integrin alpha3 | 2 | 2021 | 18 | 0.830 |
Why?
|
MicroRNAs | 3 | 2022 | 301 | 0.830 |
Why?
|
Cell Movement | 4 | 2021 | 373 | 0.810 |
Why?
|
Acetate-CoA Ligase | 1 | 2022 | 9 | 0.790 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2022 | 167 | 0.770 |
Why?
|
Molecular Targeted Therapy | 4 | 2022 | 135 | 0.770 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2022 | 39 | 0.760 |
Why?
|
Cell Culture Techniques | 2 | 2020 | 116 | 0.740 |
Why?
|
STAT3 Transcription Factor | 5 | 2025 | 97 | 0.740 |
Why?
|
Genetic Heterogeneity | 2 | 2020 | 31 | 0.730 |
Why?
|
Transforming Growth Factor beta | 1 | 2022 | 79 | 0.730 |
Why?
|
BRCA2 Protein | 1 | 2021 | 19 | 0.720 |
Why?
|
BRCA1 Protein | 1 | 2021 | 24 | 0.720 |
Why?
|
Cell Plasticity | 1 | 2021 | 10 | 0.710 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 155 | 0.710 |
Why?
|
Adenosine | 1 | 2021 | 33 | 0.710 |
Why?
|
Prognosis | 11 | 2025 | 802 | 0.690 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 45 | 0.660 |
Why?
|
Integrin beta1 | 1 | 2019 | 15 | 0.660 |
Why?
|
Vulnerable Populations | 1 | 2020 | 47 | 0.650 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 48 | 0.640 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2021 | 163 | 0.640 |
Why?
|
Breast Neoplasms | 3 | 2024 | 459 | 0.640 |
Why?
|
Deoxycytidine | 1 | 2019 | 65 | 0.630 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 409 | 0.630 |
Why?
|
Tartrate-Resistant Acid Phosphatase | 1 | 2019 | 7 | 0.620 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 250 | 0.620 |
Why?
|
Healthcare Disparities | 1 | 2020 | 90 | 0.620 |
Why?
|
Transcription Factors | 3 | 2023 | 520 | 0.610 |
Why?
|
Osteoclasts | 1 | 2019 | 29 | 0.610 |
Why?
|
Epithelial Cells | 1 | 2020 | 248 | 0.600 |
Why?
|
rab GTP-Binding Proteins | 1 | 2018 | 33 | 0.590 |
Why?
|
Claudin-1 | 1 | 2018 | 7 | 0.590 |
Why?
|
Cell Proliferation | 9 | 2022 | 806 | 0.590 |
Why?
|
Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.590 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 5 | 2022 | 13 | 0.570 |
Why?
|
RNA, Long Noncoding | 4 | 2020 | 32 | 0.560 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 42 | 0.540 |
Why?
|
Health Literacy | 3 | 2022 | 33 | 0.520 |
Why?
|
Neoplasm Metastasis | 7 | 2021 | 162 | 0.510 |
Why?
|
Cell Differentiation | 1 | 2019 | 407 | 0.510 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 453 | 0.510 |
Why?
|
Mice, Nude | 7 | 2021 | 331 | 0.490 |
Why?
|
Heterografts | 8 | 2021 | 66 | 0.440 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2020 | 269 | 0.400 |
Why?
|
Female | 15 | 2025 | 15153 | 0.380 |
Why?
|
Muscles | 2 | 2022 | 73 | 0.380 |
Why?
|
Spheroids, Cellular | 3 | 2021 | 53 | 0.380 |
Why?
|
Organoids | 2 | 2022 | 21 | 0.370 |
Why?
|
Disease Progression | 3 | 2025 | 473 | 0.370 |
Why?
|
B7-H1 Antigen | 2 | 2021 | 38 | 0.370 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 194 | 0.360 |
Why?
|
Proteomics | 3 | 2022 | 181 | 0.340 |
Why?
|
Survival Analysis | 2 | 2021 | 288 | 0.330 |
Why?
|
Male | 10 | 2025 | 13489 | 0.330 |
Why?
|
Phosphorylation | 2 | 2022 | 578 | 0.320 |
Why?
|
ErbB Receptors | 4 | 2023 | 100 | 0.300 |
Why?
|
Models, Biological | 6 | 2021 | 466 | 0.290 |
Why?
|
Muscle, Skeletal | 2 | 2024 | 634 | 0.270 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 14 | 0.270 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 300 | 0.260 |
Why?
|
Membrane Proteins | 2 | 2020 | 484 | 0.260 |
Why?
|
Neoplastic Stem Cells | 3 | 2022 | 141 | 0.250 |
Why?
|
Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.240 |
Why?
|
Glycogen Synthase Kinase 3 beta | 2 | 2022 | 42 | 0.240 |
Why?
|
Neoplasm Staging | 4 | 2020 | 478 | 0.240 |
Why?
|
Glycolysis | 2 | 2022 | 85 | 0.230 |
Why?
|
Survival Rate | 3 | 2020 | 430 | 0.220 |
Why?
|
DNA Copy Number Variations | 2 | 2021 | 36 | 0.220 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 226 | 0.210 |
Why?
|
Tumor Burden | 2 | 2021 | 110 | 0.210 |
Why?
|
PTEN Phosphohydrolase | 1 | 2023 | 29 | 0.200 |
Why?
|
Transcriptome | 1 | 2024 | 214 | 0.200 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 90 | 0.200 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 73 | 0.200 |
Why?
|
Lysosomes | 1 | 2023 | 56 | 0.200 |
Why?
|
Dynamin II | 1 | 2022 | 13 | 0.200 |
Why?
|
Tumor Necrosis Factors | 1 | 2022 | 15 | 0.200 |
Why?
|
Adenosine Monophosphate | 1 | 2022 | 21 | 0.200 |
Why?
|
Dextrans | 1 | 2022 | 23 | 0.200 |
Why?
|
Syndecan-1 | 1 | 2022 | 13 | 0.200 |
Why?
|
Mutation | 3 | 2021 | 845 | 0.200 |
Why?
|
Eukaryotic Initiation Factor-2 | 1 | 2022 | 20 | 0.190 |
Why?
|
Gene Knockdown Techniques | 2 | 2019 | 134 | 0.190 |
Why?
|
Cyclin D1 | 1 | 2022 | 38 | 0.190 |
Why?
|
Random Allocation | 2 | 2019 | 151 | 0.190 |
Why?
|
Programmed Cell Death 1 Ligand 2 Protein | 1 | 2021 | 2 | 0.190 |
Why?
|
Cell Communication | 2 | 2019 | 68 | 0.190 |
Why?
|
Purines | 1 | 2021 | 16 | 0.190 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 2021 | 5 | 0.190 |
Why?
|
Immunologic Factors | 1 | 2022 | 49 | 0.190 |
Why?
|
Cellular Reprogramming | 1 | 2021 | 10 | 0.190 |
Why?
|
Wnt Signaling Pathway | 2 | 2022 | 57 | 0.190 |
Why?
|
Biomarkers | 2 | 2022 | 765 | 0.190 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 6 | 0.190 |
Why?
|
Immune Evasion | 1 | 2021 | 8 | 0.180 |
Why?
|
DNA Repair | 1 | 2022 | 82 | 0.180 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2022 | 109 | 0.180 |
Why?
|
Dexamethasone | 1 | 2021 | 63 | 0.180 |
Why?
|
DNA-Binding Proteins | 2 | 2022 | 490 | 0.180 |
Why?
|
Lipids | 1 | 2022 | 208 | 0.180 |
Why?
|
Area Under Curve | 1 | 2021 | 95 | 0.180 |
Why?
|
ROC Curve | 1 | 2021 | 144 | 0.170 |
Why?
|
Prostaglandin D2 | 1 | 2020 | 6 | 0.170 |
Why?
|
Adenine | 1 | 2020 | 17 | 0.170 |
Why?
|
Methyltransferases | 1 | 2020 | 13 | 0.170 |
Why?
|
DNA Damage | 1 | 2022 | 151 | 0.170 |
Why?
|
Treatment Outcome | 2 | 2025 | 2377 | 0.170 |
Why?
|
Immunohistochemistry | 2 | 2019 | 463 | 0.170 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 147 | 0.170 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 190 | 0.170 |
Why?
|
Quarantine | 1 | 2020 | 4 | 0.170 |
Why?
|
NF-KappaB Inhibitor alpha | 1 | 2020 | 8 | 0.170 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 21 | 0.170 |
Why?
|
E2F1 Transcription Factor | 1 | 2020 | 3 | 0.170 |
Why?
|
Travel | 1 | 2020 | 12 | 0.170 |
Why?
|
Feedback, Physiological | 1 | 2020 | 11 | 0.170 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 148 | 0.170 |
Why?
|
beta Catenin | 1 | 2020 | 66 | 0.170 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 187 | 0.170 |
Why?
|
Phenotype | 3 | 2019 | 680 | 0.160 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 29 | 0.160 |
Why?
|
Phosphoglycerate Mutase | 1 | 2019 | 2 | 0.160 |
Why?
|
Disease Outbreaks | 1 | 2020 | 53 | 0.160 |
Why?
|
Energy Metabolism | 1 | 2021 | 200 | 0.160 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 38 | 0.160 |
Why?
|
Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.160 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.160 |
Why?
|
Databases, Factual | 1 | 2021 | 253 | 0.160 |
Why?
|
Fluorouracil | 1 | 2019 | 58 | 0.160 |
Why?
|
Mixed Function Oxygenases | 1 | 2019 | 19 | 0.160 |
Why?
|
Hepatocytes | 1 | 2020 | 80 | 0.160 |
Why?
|
Betacoronavirus | 1 | 2020 | 39 | 0.160 |
Why?
|
Ketoglutarate Dehydrogenase Complex | 1 | 2019 | 4 | 0.160 |
Why?
|
Twist-Related Protein 1 | 1 | 2019 | 5 | 0.160 |
Why?
|
Calcium-Binding Proteins | 1 | 2019 | 62 | 0.160 |
Why?
|
Receptors, Notch | 1 | 2019 | 45 | 0.160 |
Why?
|
Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2019 | 4 | 0.160 |
Why?
|
Muscle Proteins | 1 | 2019 | 56 | 0.160 |
Why?
|
Glioma | 1 | 2020 | 117 | 0.160 |
Why?
|
Health Status Disparities | 1 | 2020 | 65 | 0.160 |
Why?
|
Tandem Mass Spectrometry | 2 | 2017 | 113 | 0.160 |
Why?
|
Soft Tissue Neoplasms | 1 | 2019 | 10 | 0.160 |
Why?
|
Peptides | 1 | 2021 | 288 | 0.160 |
Why?
|
Severity of Illness Index | 1 | 2021 | 452 | 0.160 |
Why?
|
Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
Receptors, Interleukin-8B | 1 | 2019 | 6 | 0.160 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 53 | 0.160 |
Why?
|
Public Health | 1 | 2020 | 93 | 0.160 |
Why?
|
Sarcoma | 1 | 2019 | 29 | 0.160 |
Why?
|
Proteome | 1 | 2019 | 77 | 0.160 |
Why?
|
NF-kappa B | 1 | 2020 | 191 | 0.160 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 2019 | 9 | 0.160 |
Why?
|
RANK Ligand | 1 | 2019 | 19 | 0.160 |
Why?
|
RAW 264.7 Cells | 1 | 2019 | 21 | 0.150 |
Why?
|
NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2018 | 2 | 0.150 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 25 | 0.150 |
Why?
|
Telemedicine | 1 | 2022 | 174 | 0.150 |
Why?
|
Oxidative Phosphorylation | 1 | 2018 | 29 | 0.150 |
Why?
|
Cisplatin | 1 | 2019 | 179 | 0.150 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 45 | 0.150 |
Why?
|
Immunogenicity, Vaccine | 1 | 2018 | 4 | 0.150 |
Why?
|
Cohort Studies | 1 | 2021 | 887 | 0.150 |
Why?
|
Cancer Vaccines | 1 | 2018 | 33 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 44 | 0.150 |
Why?
|
Pandemics | 1 | 2020 | 186 | 0.150 |
Why?
|
Reference Values | 1 | 2018 | 199 | 0.150 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 63 | 0.150 |
Why?
|
Pancreatectomy | 1 | 2018 | 58 | 0.150 |
Why?
|
Adjuvants, Immunologic | 1 | 2018 | 68 | 0.150 |
Why?
|
RNA, Messenger | 1 | 2020 | 659 | 0.150 |
Why?
|
Cell Cycle | 2 | 2018 | 161 | 0.150 |
Why?
|
Photochemotherapy | 1 | 2018 | 42 | 0.150 |
Why?
|
Middle Aged | 5 | 2021 | 7137 | 0.140 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 281 | 0.140 |
Why?
|
Nanoparticles | 1 | 2021 | 287 | 0.140 |
Why?
|
Recombinant Proteins | 1 | 2019 | 413 | 0.140 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2018 | 122 | 0.140 |
Why?
|
Predictive Value of Tests | 2 | 2017 | 474 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 2 | 2023 | 666 | 0.140 |
Why?
|
Nuclear Proteins | 1 | 2019 | 247 | 0.140 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 521 | 0.140 |
Why?
|
Methylation | 3 | 2023 | 24 | 0.130 |
Why?
|
Transcription, Genetic | 1 | 2018 | 403 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 105 | 0.130 |
Why?
|
Macrophages | 1 | 2019 | 295 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 163 | 0.120 |
Why?
|
Apoptosis | 4 | 2021 | 775 | 0.120 |
Why?
|
Pancreas | 3 | 2023 | 61 | 0.120 |
Why?
|
Pharmacogenetics | 1 | 2015 | 6 | 0.120 |
Why?
|
Mitochondria | 1 | 2018 | 369 | 0.120 |
Why?
|
Pancreatitis, Chronic | 1 | 2015 | 6 | 0.120 |
Why?
|
Polycomb Repressive Complex 2 | 1 | 2015 | 3 | 0.120 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 276 | 0.120 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2014 | 7 | 0.120 |
Why?
|
Cell Survival | 3 | 2021 | 409 | 0.120 |
Why?
|
Esophageal Neoplasms | 1 | 2014 | 32 | 0.110 |
Why?
|
Patient Selection | 1 | 2015 | 148 | 0.110 |
Why?
|
Protein Binding | 3 | 2021 | 658 | 0.110 |
Why?
|
Lung Neoplasms | 1 | 2017 | 356 | 0.100 |
Why?
|
Cytokines | 1 | 2014 | 447 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2021 | 103 | 0.090 |
Why?
|
Carcinogenesis | 2 | 2020 | 81 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2020 | 120 | 0.080 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 315 | 0.080 |
Why?
|
Computational Biology | 2 | 2021 | 155 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 371 | 0.060 |
Why?
|
Intraepithelial Lymphocytes | 1 | 2024 | 3 | 0.060 |
Why?
|
Chitosan | 1 | 2024 | 34 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2018 | 1013 | 0.060 |
Why?
|
TNF Receptor-Associated Factor 6 | 1 | 2023 | 6 | 0.050 |
Why?
|
NFATC Transcription Factors | 1 | 2023 | 14 | 0.050 |
Why?
|
Lysine | 1 | 2023 | 74 | 0.050 |
Why?
|
Wnt Proteins | 1 | 2022 | 34 | 0.050 |
Why?
|
Tumor Escape | 1 | 2021 | 11 | 0.050 |
Why?
|
Cetuximab | 1 | 2021 | 21 | 0.050 |
Why?
|
Aged | 3 | 2017 | 5400 | 0.050 |
Why?
|
Glycosylation | 1 | 2021 | 70 | 0.050 |
Why?
|
Lymphocyte Count | 1 | 2021 | 15 | 0.050 |
Why?
|
Mice, Inbred C3H | 1 | 2021 | 74 | 0.050 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2021 | 31 | 0.050 |
Why?
|
Metabolic Networks and Pathways | 1 | 2021 | 49 | 0.050 |
Why?
|
Neoplasms, Experimental | 1 | 2021 | 58 | 0.050 |
Why?
|
Particle Size | 1 | 2021 | 101 | 0.050 |
Why?
|
Materials Testing | 1 | 2021 | 89 | 0.050 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 58 | 0.050 |
Why?
|
Databases, Genetic | 1 | 2021 | 48 | 0.050 |
Why?
|
Acculturation | 1 | 2021 | 15 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2017 | 2021 | 0.040 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2021 | 42 | 0.040 |
Why?
|
China | 1 | 2021 | 61 | 0.040 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 60 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 59 | 0.040 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 50 | 0.040 |
Why?
|
Protein Transport | 1 | 2021 | 158 | 0.040 |
Why?
|
Language | 1 | 2021 | 63 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2020 | 58 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 39 | 0.040 |
Why?
|
SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
RNA Stability | 1 | 2020 | 28 | 0.040 |
Why?
|
alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
Hep G2 Cells | 1 | 2020 | 31 | 0.040 |
Why?
|
Metabolomics | 1 | 2021 | 85 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2020 | 9 | 0.040 |
Why?
|
Whole Exome Sequencing | 1 | 2020 | 9 | 0.040 |
Why?
|
Pathology, Clinical | 1 | 2020 | 11 | 0.040 |
Why?
|
Gene Silencing | 1 | 2020 | 65 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2021 | 87 | 0.040 |
Why?
|
Allosteric Regulation | 1 | 2019 | 20 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2019 | 31 | 0.040 |
Why?
|
Mice, SCID | 1 | 2019 | 61 | 0.040 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 72 | 0.040 |
Why?
|
SMARCB1 Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2019 | 87 | 0.040 |
Why?
|
Binding Sites | 1 | 2020 | 353 | 0.040 |
Why?
|
Trisomy | 1 | 2019 | 19 | 0.040 |
Why?
|
Chemokine CXCL5 | 1 | 2019 | 7 | 0.040 |
Why?
|
Chemokine CXCL1 | 1 | 2019 | 7 | 0.040 |
Why?
|
Ligands | 1 | 2019 | 176 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2019 | 55 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2020 | 131 | 0.040 |
Why?
|
Molecular Structure | 1 | 2019 | 243 | 0.040 |
Why?
|
Extracellular Matrix | 1 | 2019 | 117 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2020 | 165 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 961 | 0.040 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 4 | 0.040 |
Why?
|
Chemoprevention | 1 | 2018 | 32 | 0.040 |
Why?
|
Surveys and Questionnaires | 1 | 2022 | 971 | 0.040 |
Why?
|
Gene Targeting | 1 | 2017 | 20 | 0.040 |
Why?
|
Cyclooxygenase 2 | 1 | 2018 | 68 | 0.040 |
Why?
|
Databases, Protein | 1 | 2017 | 22 | 0.040 |
Why?
|
RNA Interference | 1 | 2018 | 137 | 0.040 |
Why?
|
Gene Editing | 1 | 2017 | 22 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 2018 | 365 | 0.030 |
Why?
|
Histones | 1 | 2017 | 93 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2017 | 138 | 0.030 |
Why?
|
Gene Expression | 1 | 2019 | 417 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 198 | 0.030 |
Why?
|
Lymphocytes | 1 | 2017 | 90 | 0.030 |
Why?
|
Antioxidants | 1 | 2018 | 223 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 343 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2017 | 722 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 1574 | 0.030 |
Why?
|
Gastroscopy | 1 | 2014 | 7 | 0.030 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 71 | 0.030 |
Why?
|
United States | 1 | 2021 | 2146 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 60 | 0.030 |
Why?
|
Transfection | 1 | 2015 | 318 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2018 | 668 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 126 | 0.030 |
Why?
|
Blotting, Western | 1 | 2015 | 514 | 0.030 |
Why?
|
Child | 1 | 2019 | 2242 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 474 | 0.020 |
Why?
|
Young Adult | 1 | 2019 | 2732 | 0.020 |
Why?
|
Adult | 1 | 2015 | 7739 | 0.010 |
Why?
|